Cite
HARVARD Citation
Reich, K. et al. (n.d.). 309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. British journal of dermatology. p. . [Online].